Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: An association study in New Zealand Caucasians and meta-analysis

doi:10.3748/wjg.v19.i39.6656

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 39

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7933)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

537

HTML

4666

Figures (1-1)

313

Tables (1-4)

272

Sum=5788

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1133

Download

1012

Sum=2145

Oct 21, 2013 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. Oct 21, 2013; 19(39): 6656-6664
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6656

Table 1 Characteristics of previously published association studies of MIF -173G > C in inflammatory bowel disease

Cohort	Sample size	Demographics				Ref.
Cohort	Sample size	Race	mean ± SD	% male	IBD diagnosis	Ref.
1	Cases: 111	Japanese	39 ± 14.2	52.3	UC	[18]
1	Controls: 209	Japanese	44 ± 18.4	58.4	NA	[18]
2	Cases: 221	Japanese	40.1 ± 14.0	46.2	UC	[15]
2	Controls: 312	Japanese	41.4 ± 18.1	50.3	NA	[15]
3	Cases: 99	Han Chinese	38.4 ± 10.6	61.6	CD (15); UC (84)	[13]
3	Controls: 142	Han Chinese	42.3 ± 11.6	64.1	NA	[13]
4	Cases: 623	Caucasian	-	48 (CD); 49.0 (UC)	CD (336); UC (287)	[16]
4	Controls: 361		-	-	NA	[16]
5	Cases: 672	Caucasian	-	47.1 (CD); 43.0 (UC)	CD (325); UC (347)	[16]
5	Controls: 526		-	-	NA	[16]
6	Cases: 99	Caucasian	-	-	41 (CD); 58 (UC)	[17]
6	Controls: 123	Caucasian	-	-	NA	[17]
7	Cases: 198	Caucasian	39.5 ± 11.9	48.0	CD	[12]
7	Controls: 159	Caucasian	44.1 ± 15.8	46.5	NA	[12]
8	Cases: 259	Caucasian	42.3 ± 10.2 (CD); 44.1 ± 15.3 (UC)	-	157 (CD), 102 (UC)	[14]
8	Controls: 489	Caucasian	-	-	NA	[14]
9	Cases: 1234	Caucasian	-	47.2	CD	[32]
9	Controls: 2112	Caucasian	-	51.0	NA	[32]
10	Cases: 590	Caucasian	21 ± 10.8	47.2	CD	[33,34]
	Controls: 678		-	49.3	NA
	Controls: 488		44.9 ± 11.2	41.2	NA
12	Cases: 139	Caucasian (Indian)	41.0 ± 14.11	59.3	139 (UC)	[19]¹
	Controls: 176	Caucasian (Indian)	41.0 ± 14.11	59.3	NA	[19]¹

¹The study of Sivaram et al[19] was not included in the meta-analyses as study participants were neither East Asian, nor Northern European or American Caucasians. IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; NA: Not available.

Table 2 Baseline characteristics of the New Zealand inflammatory bowel disease patients and controls n (%)

Characteristic	Controls	CD	UC	IBD-U
Number of females	340 (63.0)	307 (63.0)	242 (51.5)	13 (50.0)
Age at first diagnosis (yr)
< 17		57 (11.3)	28 (5.9)
17-40		277 (55.0)	231 (48.6)	15 (55)
> 40		170 (33.7)	216 (45.5)	12 (45)
CD location
Colonic		211 (41.8)
Ileocaecal		125 (24.8)
Ileal		64 (32.5)
Isolated upper GI disease		3 (0.6)
Perianal disease modifier		136 (27.0)
CD behaviour
Non-stricturing/ non-penetrating		286 (56.8)
Penetrating		57 (11.3)
Stricturing		161 (31.9)
UC location
Proctitis			164 (34.5)	3 (11.1)
Left-sided			125 (26.3)	5 (18.5)
Extensive			181 (38.1)	19 (70.4)

IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; GI: Gastrointestinal.

Table 3 Allele and genotype frequencies of MIF-173G > C in New Zealand Caucasian patients with inflammatory bowel disease compared with controls

Phenotype	Genotype			MAF	Allelic P (unadjusted)	OR (95%CI)
Phenotype	GG	GC	CC	MAF	Allelic P (unadjusted)	OR (95%CI)
Control	328 (0.672)	143 (0.293)	17 (0.035)	177 (0.181)
IBD	668 (0.676)	287 (0.290)	33 (0.033)	353 (0.179)	0.86	0.98 (0.80-1.20)
UC	320 (0.687)	129 (0.277)	17 (0.036)	163 (0.175)	0.71	0.96 (0.76-1.21)
Age at first diagnosis (yr)
< 17	17 (0.610)	11 (0.390)	0	11 (0.196)	0.78	1.10 (0.56-2.18)
17-40	153 (0.680)	60 (0.267)	12 (0.053)	84 (0.187)	0.81	1.04 (0.78-1.38)
> 40	150 (0.704)	58 (0.272)	5 (0.023)	68 (0.160)	0.33	0.86 (0.63-1.17)
Disease location
Proctitis	106 (0.658)	49 (0.304)	6 (0.037)	61 (0.189)	0.75	1.06 (0.76-1.46)
Left-sided	92 (0.742)	27 (0.218)	5 (0.040)	37 (0.149)	0.23	0.79 (0.54-1.16)
Extensive	118 (0.670)	52 (0.295)	6 (0.034)	64 (0.182)	0.99	1.00 (0.73-1.38)
CD	331 (0.669)	149 (0.301)	15 (0.030)	179 (0.181)	0.98	0.00 (0.79-1.25)
Age at first diagnosis (yr)
< 17	36 (0.642)	19 (0.339)	1 (0.017)	21 (0.188)	0.87	1.04 (0.63-1.72)
17-40	188 (0.683)	81 (0.295)	6 (0.220)	93 (0.169)	0.55	0.92 (0.70-1.21)
> 40	107 (0.652)	49 (0.299)	8 (0.049)	65 (0.198)	0.50	1.12 (0.81-1.53)
Disease location
Colonic	131 (0.633)	68 (0.328)	8 (0.039)	84 (0.203)	0.35	1.15 (0.86-1.54)
Ileocaecal	81 (0.653)	37 (0.298)	6 (0.048)	49 (0.198)	0.56	1.11 (0.78-1.58)
Ileal	115 (0.719)	44 (0.275)	1 (0.006)	46 (0.144)	0.12	0.76 (0.53-1.08)
Disease behaviour
Non-stricturing/non-penetrating	181 (0.644)	92 (0.327)	8 (0.028)	108 (0.192)	0.60	1.07 (0.82-1.40)
Penetrating	37 (0.649)	19 (0.333)	1 (0.018)	21 (0.184)	0.94	1.02 (0.62-1.68)
Stricturing	113 (0.720)	38 (0.242)	6 (0.038)	50 (0.159)	0.37	0.86 (0.61-1.21)

IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease.

Table 4 Allele and genotype frequencies of MIF CATT5-8 haplotypes in New Zealand Caucasian controls and inflammatory bowel disease patients

Phenotype	Genotype^a			MAF	Allelic P (unadjusted)	OR (95%CI)
Phenotype	5/5	5/X	X/X	MAF	Allelic P (unadjusted)	OR (95%CI)
Control	27 (0.050)	187 (0.350)	321 (0.600)	241 (0.225)
IBD	54 (0.055)	366 (0.375)	555 (0.569)	474 (0.243)	0.27	1.10 (0.93-1.32)
UC	24 (0.051)	172 (0.364)	277 (0.586)	220 (0.233)	0.70	1.04 (0.85-1.28)
Age at first diagnosis (yr)
< 17	0	11 (0.393)	17 (0.607)	11 (0.196)	0.61	1.04 (0.43-1.65)
17-40	10 (0.043)	91 (0.394)	130 (0.563)	111 (0.240)	0.52	1.09 (0.84-1.41)
> 40	14 (0.065)	70 (0.327)	130 (0.607)	98 (0.229)	0.88	1.02 (0.78-1.33)
Disease location
Proctitis	12 (0.073)	56 (0.341)	96 (0.585)	80 (0.244)	0.48	1.11 (0.83-1.48)
Left-sided	5 (0.040)	48 (0.387)	71 (0.573)	58 (0.234)	0.77	1.05 (0.76-1.46)
Extensive	7 (0.039)	67 (0.372)	106 (0.589)	81 (0.225)	0.99	1.00 (0.75-1.33)
CD	30 (0.063)	182 (0.555)	264 (0.555)	242 (0.254)	0.12	1.18 (0.96-1.44)
Age at first diagnosis (yr)
< 17	4 (0.073)	22 (0.400)	29 (0.527)	30 (0.273)	0.26	1.29 (0.83-2.01)
17-40	15 (0.057)	104 (0.394)	145 (0.549)	134 (0.254)	0.21	1.17 (0.92-1.49)
> 40	11 (0.070)	56 (0.357)	90 (0.573)	78 (0.248)	0.39	1.14 (0.85-1.52)
Disease location
Colonic	14 (0.070)	75 (0.375)	111 (0.555)	103 (0.258)	0.19	1.19 (0.91-1.56)
Ileocaecal	7 (0.058)	48 (0.397)	66 (0.545)	62 (0.256)	0.19	1.19 (0.86-1.64)
Ileal	9 (0.060)	56 (0.371)	86 (0.570)	74 (0.245)	0.47	1.12 (0.83-1.51)
Disease behaviour
Non-stricturing/non-penetrating	18 (0.066)	104 (0.382)	150 (0.551)	140 (0.257)	0.15	1.19 (0.94-1.51)
Penetrating	1 (0.019)	20 (0.377)	32 (0.604)	22 (0.208)	0.68	0.90 (0.55-1.47)
Stricturing	11 (0.073)	58 (0.384)	82 (0.543)	80 (0.265)	0.15	1.24 (0.93-1.66)

^aX = 6, 7, or 8 CATT repeats. IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease.

Citation: Falvey JD, Bentley RW, Merriman TR, Hampton MB, Barclay ML, Gearry RB, Roberts RL. Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: An association study in New Zealand Caucasians and meta-analysis. World J Gastroenterol 2013; 19(39): 6656-6664
URL: https://www.wjgnet.com/1007-9327/full/v19/i39/6656.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i39.6656